ArticleFrontiers in immunology2026

HDAC3 inhibition as a therapeutic strategy in T-cell acute lymphoblastic leukemia via the TYK2-STAT1-BCL2 signaling pathway.

Zhenyang Gu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.